EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

Selection of effective LRAs using a newly designed in vitro HIV latency reactivation protocol: toward future application in HIV samples

Alessia Neri iD, Arianna Rotili iD, Elena Morrocchi, Giuseppe Rubens Pascucci, Chiara Pighi, Giulio Olivieri, Federica Betto, Elena Emili, Ridika Karmakar, Daniela Iaconis, Filippo Lunghini, Gabriele Coppola und 3 weitere

Microbiology Spectrum · 2026

DOI: 10.1128/spectrum.00407-26 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Microbiology Spectrum, 2026. Verfasst von Alessia Neri und 14 weiteren Autor:innen. Beteiligte Einrichtung: PhD Program in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Rome, Italy. Hauptthemen laut MEDLINE: Virus Latency, HIV-1, Virus Activation, Anti-HIV Agents. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human immunodeficiency virus type 1 (HIV-1) persists in latent reservoirs, mainly within CD4 + T cells, which are refractory to antiretroviral therapy, and can lead to rapid viral rebound upon treatment interruption. The “shock and kill” strategy aims to eliminate latent reservoirs by inducing viral transcription through latency-reversing agents (LRAs), thereby exposing infected cells to immune-mediated clearance. We developed and validated a simple, low-cost, and highly reproducible in vitro screening protocol to evaluate the efficacy and safety of LRAs, using a two-color flow cytometry assay on ACH2 cells, a well-characterized model of HIV-1 latency. Using this method, we identified PEP005 and CUDC-907 as the most potent LRAs across multiple experimental settings. Their reactivation capacity was further confirmed through transcriptomic analysis, which revealed a significant upregulation of viral RNA copies following stimulation. In addition, we collaborated with Dompé for using the Exscalate platform, an innovative computer-aided drug discovery approach, together with the experimental validation, which led to the identification of Tandutinib, a tyrosine kinase and mTOR inhibitor, as a novel LRA candidate with appreciable latency-reversing activity in the ACH2 model. While the ACH2 cell line does not fully recapitulate the complexity of HIV latency in vivo , it offers a robust and scalable system for early-stage screening and prioritization of candidate LRAs. Importantly, the future application of these LRAs in ex vivo samples derived from people living with HIV, with a particular focus on pediatric samples, will be crucial to deepen our understanding of latency reactivation in clinically relevant settings and age-specific immune environments. IMPORTANCE This study addresses a major obstacle to curing human immunodeficiency virus type 1 (HIV-1) infection: the persistence of latent viral reservoirs that are not eliminated by current therapies. We developed a simple and reproducible assay to identify compounds capable of reactivating latent virus, a key step in cure strategies. Using this approach, we identified effective latency-reversing compounds and, through collaboration with Dompé using the EXSCALATE platform, we also identified Tandutinib as a promising new candidate for further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Virus LatencyHIV-1Virus ActivationAnti-HIV AgentsHIV InfectionsHumansCell LineCD4-Positive T-LymphocytesFlow CytometryDrug DiscoveryDrug Evaluation, Preclinical

Stichwörter der Autor:innen

HIV curecomputer-aided drug discoveryin vitro modelslatencylatency reversal

Substanzen

Anti-HIV Agents

Autor:innen und Institutionen

  • PhD Program in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Rome, Italy.
  • Clinical Immunology and Vaccinology Unit, IRCCS, Bambino Gesù Children's Hospital, Rome, Italy.
  • Probiomics S.r.l., Rome, Italy.
  • Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
  • EXSCALATE, Dompé Farmaceutici SpA, Naples, Italy.
  • Chair of Pediatrics, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.

ORCID-Profile: Alessia Neri, Arianna Rotili, Paolo Palma

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Neri, A., Rotili, A., Morrocchi, E., Pascucci, G. R., Pighi, C., Olivieri, G., Betto, F., Emili, E., Karmakar, R., Iaconis, D., Lunghini, F., Coppola, G., Amodio, D., Cotugno, N., & Palma, P. (2026). Selection of effective LRAs using a newly designed in vitro HIV latency reactivation protocol: toward future application in HIV samples. Microbiology Spectrum. https://doi.org/10.1128/spectrum.00407-26

Vancouver

Neri A, Rotili A, Morrocchi E, Pascucci GR, Pighi C, Olivieri G, et al. Selection of effective LRAs using a newly designed in vitro HIV latency reactivation protocol: toward future application in HIV samples. Microbiology Spectrum. 2026. doi:10.1128/spectrum.00407-26

BibTeX
@article{Neri2026,
  author = {Neri, Alessia and Rotili, Arianna and Morrocchi, Elena and Pascucci, Giuseppe Rubens and Pighi, Chiara and Olivieri, Giulio and Betto, Federica and Emili, Elena and Karmakar, Ridika and Iaconis, Daniela and Lunghini, Filippo and Coppola, Gabriele and Amodio, Donato and Cotugno, Nicola and Palma, Paolo},
  title = {Selection of effective LRAs using a newly designed in vitro HIV latency reactivation protocol: toward future application in HIV samples},
  journal = {Microbiology Spectrum},
  year = {2026},
  doi = {10.1128/spectrum.00407-26}
}
Kostenlos starten →